专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明授权

US09387238B2 CDCA1 epitope peptides and vaccines containing the same 有权
标题翻译： CDCA1表位肽和含有它们的疫苗
公开(公告)号：US09387238B2
公开(公告)日：2016-07-12
申请号：US12999051
申请日：2009-06-18
申请人： Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura
发明人： Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura
IPC分类号： A61K38/00 , A61K39/00 , C07K14/47 , C07K14/74
CPC分类号： C07K14/4748 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/5154 , A61K2039/53 , A61K2039/572 , A61K2039/575 , C07K14/47 , C12N5/0638
摘要： Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from CDCA1 that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A24 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical agents containing the CDCA1 polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients. Furthermore, the present invention provides methods for treating and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the CDCA1 polypeptides, polynucleotides encoding the polypeptides, exosomes or antigen-presenting cells presenting the polypeptides, or the pharmaceutical agents of the present invention. The cancers to be targeted include, but are not limited to, breast cancer, bladder cancer, esophageal cancer, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
摘要翻译：本文描述了针对癌症的肽疫苗。特别地，本发明描述了衍生自引起CTL的CDCA1的表位肽。本发明还提供了特异性识别用肽脉冲的HLA-A24阳性靶细胞的已建立的CTL。还提供了呈递任何肽的抗原呈递细胞和外来体以及诱导抗原呈递细胞的方法。本发明还提供含有CDCA1多肽或其编码多核苷酸以及作为活性成分的外来体和抗原呈递细胞的药剂。此外，本发明提供了治疗和/或预防（即预防）癌症（肿瘤）和/或预防其术后复发的方法，以及诱导CTL的方法，诱导抗肿瘤免疫的方法，使用 CDCA1多肽，编码多肽的多核苷酸，呈递多肽的外来体或抗原呈递细胞，或本发明的药剂。要靶向的癌症包括但不限于乳腺癌，膀胱癌，食管癌，小细胞肺癌（SCLC）和非小细胞肺癌（NSCLC）。

32. 发明授权

US09187556B2 SEMA5B peptides and vaccines including the same 有权
标题翻译： SEMA5B肽和疫苗包括它们
公开(公告)号：US09187556B2
公开(公告)日：2015-11-17
申请号：US14118693
申请日：2012-06-07
申请人： Takuya Tsunoda , Ryuji Osawa , Sachiko Yoshimura , Tomohisa Watanabe , Gaku Nakayama , Yusuke Nakamura
发明人： Takuya Tsunoda , Ryuji Osawa , Sachiko Yoshimura , Tomohisa Watanabe , Gaku Nakayama , Yusuke Nakamura
IPC分类号： C07K14/00 , C07K16/18 , C07K14/47 , G01N33/574 , A61K39/00 , A61K38/00
CPC分类号： C07K16/18 , A61K38/00 , A61K39/0011 , C07K14/4703 , G01N33/57492 , G01N2333/70539
摘要： As discussed in detail herein, isolated epitope peptides derived from SEMA5B bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, pharmaceutical agents or compositions of this invention find particular utility in the treatment and/or prevention of cancers and tumors, including, for example, esophageal cancer, NSCLC, RCC and SCLC.
摘要翻译：如本文详细讨论的，衍生自SEMA5B的分离的表位肽结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL），因此适合用于癌症免疫治疗，尤其是癌症疫苗的上下文中。本发明的肽包括上述氨基酸序列及其修饰形式，其中一个，两个或若干个氨基酸被取代，缺失，插入或添加，只要这些修饰版本保持必需的HLA结合和/或CTL诱导性原始序列。还提供了编码任何上述肽的多核苷酸以及包括任何上述肽或多核苷酸的药物试剂或组合物。本发明的肽，多核苷酸，药物或组合物特别用于治疗和/或预防癌症和肿瘤，包括例如食管癌，NSCLC，RCC和SCLC。

33. 发明授权

US09045557B2 NEIL3 peptides and vaccines including the same 有权
标题翻译： NEIL3肽和疫苗包括它们
公开(公告)号：US09045557B2
公开(公告)日：2015-06-02
申请号：US13256580
申请日：2010-03-15
申请人： Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe , Yusuke Nakamura , Yoichi Furukawa
发明人： Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe , Yusuke Nakamura , Yoichi Furukawa
IPC分类号： A61K38/00 , C07K14/47 , A61K39/00
CPC分类号： C07K14/4748 , A61K39/00 , A61K39/0011 , A61K39/39 , A61K2039/53 , A61K2039/572 , C12N9/88 , C12Y402/99018 , Y02A50/396
摘要： The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.
摘要翻译：本发明提供分离的肽或衍生自SEQ ID NO：45的片段，其结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL）。肽可以包括具有取代缺失的上述氨基酸序列，或加入一个，两个或几个氨基酸序列。本发明还提供了包括这些肽的药物组合物。本发明的肽可用于诊断或治疗癌症。

34. 发明授权

US08951975B2 ECT2 peptides and vaccines including the same 有权
标题翻译： ECT2肽和疫苗包括它们
公开(公告)号：US08951975B2
公开(公告)日：2015-02-10
申请号：US13638272
申请日：2011-03-30
申请人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe
发明人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe
IPC分类号： A61K38/08 , A61K38/10 , A61K38/00 , A61K38/04 , C07K7/06 , A61K39/00
CPC分类号： C07K7/06 , A61K39/0011 , A61K2039/572
摘要： Isolated peptides derived from SEQ ID NO: 42 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the afore-mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophageal cancer, NSCLC, lymphoma, pancreatic cancer, prostate cancer, renal carcinoma and SCLC.
摘要翻译：衍生自SEQ ID NO：42的分离的肽及其与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的片段，因此适用于癌症免疫治疗，特别是癌症疫苗的上下文中。本发明的肽包括上述氨基酸序列及其修饰形式，其中一个，两个或几个氨基酸被取代，缺失，插入或添加，只要这些修饰版本保留所需的HLA结合和/或CTL诱导性的原始序列。还提供了编码任何前述肽的核酸以及包括或掺入任何前述肽或核酸的药物，物质和/或组合物。本发明的肽，核酸，药物，物质和组合物在治疗癌症和肿瘤方面特别有用，包括例如膀胱癌，乳腺癌，子宫颈癌，胆管细胞癌，CML，结肠直肠癌，食管癌，NSCLC，淋巴瘤，胰腺癌，前列腺癌，肾癌和SCLC。

35. 发明申请

US20140178409A1 SEMA5B PEPTIDES AND VACCINES INCLUDING THE SAME 有权
标题翻译： SEMA5B肽和疫苗，包括它们
公开(公告)号：US20140178409A1
公开(公告)日：2014-06-26
申请号：US14118693
申请日：2012-06-07
申请人： Takuya Tsunoda , Ryuji Osawa , Sachiko Yoshimura , Tomohisa Watanabe , Gaku Nakayama , Yusuke Nakamura
发明人： Takuya Tsunoda , Ryuji Osawa , Sachiko Yoshimura , Tomohisa Watanabe , Gaku Nakayama , Yusuke Nakamura
IPC分类号： C07K16/18
CPC分类号： C07K16/18 , A61K38/00 , A61K39/0011 , C07K14/4703 , G01N33/57492 , G01N2333/70539
摘要： As discussed in detail herein, isolated epitope peptides derived from SEMA5B bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, pharmaceutical agents or compositions of this invention find particular utility in the treatment and/or prevention of cancers and tumors, including, for example, esophageal cancer, NSCLC, RCC and SCLC.
摘要翻译：如本文详细讨论的，衍生自SEMA5B的分离的表位肽结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL），因此适合用于癌症免疫治疗，尤其是癌症疫苗的上下文中。本发明的肽包括上述氨基酸序列及其修饰形式，其中一个，两个或若干个氨基酸被取代，缺失，插入或添加，只要这些修饰版本保持必需的HLA结合和/或CTL诱导性原始序列。还提供了编码任何上述肽的多核苷酸以及包括任何上述肽或多核苷酸的药物试剂或组合物。本发明的肽，多核苷酸，药物或组合物特别用于治疗和/或预防癌症和肿瘤，包括例如食管癌，NSCLC，RCC和SCLC。

36. 发明授权

US08653234B2 Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides 有权
标题翻译：表达MPHOSPH1或DEPDC1多肽的癌症疫苗
公开(公告)号：US08653234B2
公开(公告)日：2014-02-18
申请号：US13535303
申请日：2012-06-27
申请人： Tomoaki Fujioka , Yusuke Nakamura , Takuya Tsunoda , Ryuji Osawa , Midori Shida
发明人： Tomoaki Fujioka , Yusuke Nakamura , Takuya Tsunoda , Ryuji Osawa , Midori Shida
IPC分类号： C07K5/00 , C12N15/00
CPC分类号： A61K39/0011 , A61K38/00 , A61K39/00 , A61K2039/54 , A61K2039/55566 , A61K2039/57 , A61K2039/572 , C07K7/06 , C07K14/4703
摘要： The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226, 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, wherein the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers, containing these peptides as an active ingredient. The peptides of the present invention can also be used as vaccines.
摘要翻译：本发明提供具有如SEQ ID NO：7,8,9,10,11,12,192,195,197,209,225,226,228,230,240,241,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,2 243,244,249,253,254或255，以及具有上述氨基酸序列的肽，其中1,2或几个氨基酸被取代，缺失或加入，其中肽具有细胞毒性T细胞诱导性。本发明还提供用于治疗或预防与MPHOSPH1和/或DEPDC1的过度表达相关的疾病的药物，例如，含有这些肽作为活性成分的癌症。本发明的肽也可以用作疫苗。

37. 发明授权

US08552146B2 Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides 有权
公开(公告)号：US08552146B2
公开(公告)日：2013-10-08
申请号：US13562250
申请日：2012-07-30
申请人： Tomoaki Fujioka , Yusuke Nakamura , Takuya Tsunoda , Ryuji Osawa , Midori Shida
发明人： Tomoaki Fujioka , Yusuke Nakamura , Takuya Tsunoda , Ryuji Osawa , Midori Shida
IPC分类号： C07K5/00 , C12P21/00
CPC分类号： A61K39/0011 , A61K38/00 , A61K39/00 , A61K2039/54 , A61K2039/55566 , A61K2039/57 , A61K2039/572 , C07K7/06 , C07K14/4703
摘要： The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226, 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, wherein the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers, containing these peptides as an active ingredient. The peptides of the present invention can also be used as vaccines.

38. 发明申请

US20130203625A1 SUV420H1 AND SUV420H2 AS TARGET GENES FOR CANCER THERAPY AND DIAGNOSIS 审中-公开
标题翻译： SUV420H1和SUV420H2作为癌症治疗和诊断的靶基因
公开(公告)号：US20130203625A1
公开(公告)日：2013-08-08
申请号：US13817812
申请日：2011-08-18
申请人： Ryuji Hamamoto , Yusuke Nakamura , Takuya Tsunoda
发明人： Ryuji Hamamoto , Yusuke Nakamura , Takuya Tsunoda
IPC分类号： G01N33/50 , C12Q1/68 , C12Q1/48 , G01N33/68
CPC分类号： G01N33/5011 , A61K31/713 , C12N15/1137 , C12N2310/14 , C12Q1/48 , C12Q1/6897 , C12Y201/01043 , G01N33/57407 , G01N33/6872 , G01N2500/04
摘要： The present invention relates to the roles played by the SUV420H1 and SUV420H2 genes in carcinogenesis and features a method for treating or preventing cancer by administering a double-stranded molecule against the SUV420H1 or SUV420H2 gene or a composition or vector containing such a double-stranded molecule. The present invention also features methods and kits for detecting or diagnosing cancer in a subject, including detecting an expression level of the SUV420H1 or SUV420H2 gene. The present invention further features methods and kits for assessing or determining the prognosis of a subject with cancer, including detecting the expression level of an SUV420H2 gene. Also, disclosed are methods of screening for candidate substances for treating or preventing cancer or inhibiting cancer cell growth, using as an index their effect on the expression or activity of SUV420H1 or SUV420H2.
摘要翻译：本发明涉及SUV420H1和SUV420H2基因在癌发生中的作用，其特征在于通过对SUV420H1或SUV420H2基因施用双链分子或含有这种双链分子的组合物或载体来治疗或预防癌症的方法。本发明还特征在于检测或诊断受试者的癌症的方法和试剂盒，包括检测SUV420H1或SUV420H2基因的表达水平。本发明还涉及用于评估或确定患有癌症的受试者的预后的方法和试剂盒，包括检测SUV420H2基因的表达水平。此外，公开了使用作为SUV420H1或SUV420H2的表达或活性的指标作为指标来筛选用于治疗或预防癌症或抑制癌细胞生长的候选物质的方法。

39. 发明申请

US20130034574A1 MODIFIED MELK PEPTIDES AND VACCINES CONTAINING THE SAME 有权
标题翻译：改良的梅毒肽和含有其的疫苗
公开(公告)号：US20130034574A1
公开(公告)日：2013-02-07
申请号：US13574774
申请日：2011-01-24
申请人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe
发明人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe
IPC分类号： A61K39/00 , C12N15/12 , C12N5/10 , C12N15/85 , C12N5/0784 , C12N5/0783 , C07K7/06 , A61P35/00
CPC分类号： C12Y207/11025 , A61K39/0011 , A61K39/39 , C12N9/1205
摘要： Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild type MELK epitope peptide and thus are suitable for use in the context of cancer immunotherapy or endometriosis immunotherapy, more particularly cancer or endometriosis vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical substances and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical substances and compositions of this invention find particular utility in the treatment of cancers, tumors, and endometriosis.
摘要翻译：由修饰的MELK表位肽或其免疫活性片段的氨基酸序列组成的分离肽，其结合HLA抗原并且具有比野生型MELK表位肽更高的细胞毒性T淋巴细胞（CTL）诱导性，因此适用于本文描述了癌症免疫治疗或子宫内膜异位症免疫治疗的背景，更特别的是癌症或子宫内膜异位症疫苗。本发明进一步提供了肽，其包括前述肽或片段的一个，两个或几个氨基酸插入，取代或添加，但仍保留所需的细胞毒性T细胞诱导性。进一步提供了编码这些上述肽中的任何一种的核酸以及包含上述肽或核酸中任何一种的药物物质和组合物。本发明的肽，核酸，药物和组合物在癌症，肿瘤和子宫内膜异位症的治疗中具有特别的用途。

40. 发明申请

US20120156231A1 FOXM1 PEPTIDES AND VACCINES CONTAINING THE SAME 有权
标题翻译： FOXM1肽和含有其的疫苗
公开(公告)号：US20120156231A1
公开(公告)日：2012-06-21
申请号：US13202078
申请日：2010-02-17
申请人： Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe
发明人： Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe
IPC分类号： A61K39/00 , C07K7/08 , C07K7/06 , C07H21/00 , C12N5/0783 , A61K48/00 , A61P37/04 , A61P35/00 , C12N5/078 , C12N15/85 , C07K14/47 , C12N15/12
CPC分类号： A61K31/7088 , A61K38/00 , A61K39/0011 , A61K2039/5158 , A61K2039/57 , C07K14/4748
摘要： The present invention provides isolated peptides having the amino acid sequence of SEQ ID NO: 34 or fragments thereof, which bind to HLA antigen and induce cytotoxic T lymphocyte (CTL). The present invention further provides peptides which include one, two, or several amino acid insertions, substitution or addition to the aforementioned peptides or fragments, but still have the cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical substances or compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical substances or compositions of the present invention may be used for treating cancer or tumor.
摘要翻译：本发明提供了具有与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的具有SEQ ID NO：34或其片段的氨基酸序列的分离的肽。本发明还提供了包括一个，两个或几个氨基酸插入，取代或加成上述肽或片段但仍具有细胞毒性T细胞诱导性的肽。进一步提供了编码这些上述肽中的任何一种的核酸以及包含任何上述肽或核酸的药物或组合物。本发明的肽，核酸，药物或组合物可用于治疗癌症或肿瘤。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式